论文部分内容阅读
目的探讨依达拉奉在脑梗死患者中对于神经功能状态的改善情况及临床效果。方法选取我院自2008年9月～2012年9月收治的脑梗死患者共105例。随机分为两组,其中对照组患者接受常规治疗,观察组患者接受常规治疗的基础上加用依达拉奉的治疗。结果对照组患者治疗前的ESS神经功能评分为(25.3±5.2)分,治疗后为(6.9±1.5)分;观察组患者治疗前的ESS神经功能评分(25.1±3.1)分,治疗后为(14.2±5.0)分。两组患者在治疗前后期神经功能评分均有改善,但观察组患者在治疗后的ESS评分明显要低于对照组患者,两组对比有显著性差异(P<0.01)。另外,两组血清中hs-CRP、磷酸酯(PA)和溶血磷脂酸(LPA)均有所下降,但观察组患者下降的幅度明显要高于对照组,两组有显著性差异(P<0.01)。结论依达拉奉能够有效改善脑梗死患者的神经状态,并且能够有效降低患者血清中hs-CRP、PA和LPA的含量,有利于预后。
Objective To investigate the improvement of neurological status and clinical effect of edaravone in patients with cerebral infarction. Methods A total of 105 patients with cerebral infarction in our hospital from September 2008 to September 2012 were selected. Randomly divided into two groups, of which patients in the control group received routine treatment, and patients in the observation group received conventional treatment based on the treatment with edaravone. Results The score of ESS before treatment in control group was (25.3 ± 5.2) points and (6.9 ± 1.5) points after treatment. The score of ESS before treatment in observation group (25.1 ± 3.1) was ( 14.2 ± 5.0) points. The scores of neurological function in both groups before and after treatment were improved, but the ESS scores in the observation group after treatment were significantly lower than those in the control group, there was significant difference between the two groups (P <0.01). In addition, serum hs-CRP, phosphate (PA) and lysophosphatidic acid (LPA) decreased in both groups, but the decrease in observation group was significantly higher than that in control group, with significant difference between the two groups (P < 0.01). Conclusion Edaravone can effectively improve the neurological state of patients with cerebral infarction, and can effectively reduce the serum hs-CRP, PA and LPA levels, is conducive to prognosis.